E-mail

E-mail a Wiley Online Library Link

Colan M. Ho-Yen, Andrew R. Green, Emad A. Rakha, Adam R. Brentnall, Ian O. Ellis, Stephanie Kermorgant and J. L. Jones C-Met in invasive breast cancer Cancer 120

Article first published online: 21 OCT 2013 | DOI: 10.1002/cncr.28386

There is currently no targeted systemic therapy for basal-like breast cancer, a subtype of invasive breast cancer with a poor prognosis. This study shows that the targetable receptor tyrosine kinase c-Met is independently associated with basal-like breast cancer, suggesting that patients with these tumors be included in future clinical trials of c-Met inhibitors.

Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf

Required = Required Field

SEARCH